Ernst & Young: "Progressions, Executing for success: powering new business models"

The Progressions report reveals findings from a global survey of senior executives from 15 major pharmaceutical companies.

It identifies the top concerns of these leaders and the progress they have made in transforming their businesses.


The report shows that the top priority for senior management is to improve the pipeline of new products.

Only 40 per cent of respondents considered the optimisation of costs to be the most important initiative, whereas in a similar survey in 2007, this was the top priority for 92 per cent of executives.

(Y estos señores, me pregunto yo..., en que mundo viven...?)


Companies are looking to drive innovation and reinvigorate R&D in the hope of transforming business models.

Mas...

Por otra parte encontramos esto que parece tambien interesante:



Mas...